NKTR-102 topoisomerase I-inhibitor

[Rich66]

ASCO 2011
http://www.nektar.com/pdf/pipeline/N...ase_2_Data.pdf

Clinical benefit rate for the 35 evaluable patients in the q21d schedule was 49% (17/35). Clinical benefit rate for the overall study population was 46%. An additional four patients in the study had near CRs, with 100% disappearance of all target lesions.
“NKTR-102 is emerging as a promising anti-cancer investigational treatment with the potential
to become the first topoisomerase I-inhibitor to be used in the fight against breast cancer,” said
Prof. Ahmad Awada, Head of the Medical Oncology Clinic at the Institut Jules Bordet in
Brussels, Belgium. “The drug’s high confirmed objective response rate and clinical benefit is
very interesting, particularly when one observes that this response rate was maintained in
patients pre-treated with anthracyclines, taxanes with or without capecitabine, and also
maintained in poor prognosis subsets within the study, such as triple-negative breast cancer
and patients with visceral disease.”
The confirmed ORR in patients previously treated with anthracycline/taxane/capecitabine was
31% (5/16); confirmed ORR in patients with metastatic triple-negative breast cancer was 39%
(7/18); and confirmed ORR in patients with visceral disease was 30% (17/57).
“The every three week dose schedule appears well-tolerated overall and demonstrates
encouraging PFS and OS of 5.3 months and 13.1 months, respectively,” continued Dr. Awada.
“We are in need of effective new therapeutic options whose mechanism of action is different
from those already available for women with metastatic breast cancer and we look forward to
NKTR-102 entering Phase 3 development.”

[Rich66]

.................................................. ................................